Effects of pretreatment with terazosin and valsartan on intraoperative haemodynamics in patients with phaeochromocytoma
ObjectiveSurgery is the primary strategy for treating phaeochromocytoma (PCC), but it can lead to severe hypertension and heart failure. Although valsartan is effective in reducing high blood pressure, clinical data on the potential role of valsartan in PCC are currently limited. Therefore, the aim...
Gespeichert in:
| Veröffentlicht in: | European journal of hospital pharmacy. Science and practice 2022-07, Vol.29 (4), p.192-197 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 197 |
|---|---|
| container_issue | 4 |
| container_start_page | 192 |
| container_title | European journal of hospital pharmacy. Science and practice |
| container_volume | 29 |
| creator | Ji, Qingrong Li, Feng Zhang, Xianzhao Wang, Yuqiang Liu, Cunfei Chang, Ying |
| description | ObjectiveSurgery is the primary strategy for treating phaeochromocytoma (PCC), but it can lead to severe hypertension and heart failure. Although valsartan is effective in reducing high blood pressure, clinical data on the potential role of valsartan in PCC are currently limited. Therefore, the aim of this study was to investigate the effects of pretreatment with terazosin and valsartan on patients with PCC.MethodsIn this retrospective cohort study, 50 patients who underwent laparoscopic resection of PCC were enrolled. During preoperative preparation, the patients (n=25) in the control group were treated with terazosin, while those (n=25) in the combination treatment group were treated with terazosin and valsartan. The levels of catecholamine hormones before and after surgery were determined, and the intraoperative blood pressure and the incidence of complications were compared between the two groups.ResultsThe results showed no significant differences in baseline patient characteristics or surgical conditions between the two groups (p>0.05). However, on the third day after surgery, the levels of catecholamine hormones in the two groups were significantly lower than those before surgery (p |
| doi_str_mv | 10.1136/ejhpharm-2020-002375 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9251171</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2483357747</sourcerecordid><originalsourceid>FETCH-LOGICAL-b471t-660dba8922fdbb104fce5f812cf04116ab8be875f6df93fc926b74eb85150cf03</originalsourceid><addsrcrecordid>eNqNkUuLFDEUhQtRnGGcfyAScOOmnLxTtRFkGB8w4EbXIUklVppOUibpHnp-vWlqpn0sxFUuud85nMvpupcIvkWI8Cu7mZdZ5dBjiGEPISaCPenOMaSiH0dOn55mxs-6y1K8hoyQYaRkfN6dETyMDBN43t3dOGdNLSA5sGRbs1U12FjBna8zqDar-1R8BCpOYK-2ReWqIkgR-FizSksDqt9bMCsb0nSIKnhT2hIs7b_5lNWohbXJzDmFZA41BfWie-aanb18eC-6bx9uvl5_6m-_fPx8_f6211Sg2nMOJ62GEWM3aY0gdcYyNyBsHKQIcaUHbQfBHJ_cSJwZMdeCWj0wxGBjyEX3bvVddjrYydhj7K1csg8qH2RSXv65iX6W39NejpghJFAzePNgkNOPnS1VBl-M3W5VtGlXJKYDIUwIKhr6-i90k3Y5tvMk5gPkXIyINIqulMmplGzdKQyC8liufCxXHsuVa7lN9ur3Q06ixyobcLUCOmz-1xL-Upyi_lPyE0MNxUQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2680667913</pqid></control><display><type>article</type><title>Effects of pretreatment with terazosin and valsartan on intraoperative haemodynamics in patients with phaeochromocytoma</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Ji, Qingrong ; Li, Feng ; Zhang, Xianzhao ; Wang, Yuqiang ; Liu, Cunfei ; Chang, Ying</creator><creatorcontrib>Ji, Qingrong ; Li, Feng ; Zhang, Xianzhao ; Wang, Yuqiang ; Liu, Cunfei ; Chang, Ying</creatorcontrib><description>ObjectiveSurgery is the primary strategy for treating phaeochromocytoma (PCC), but it can lead to severe hypertension and heart failure. Although valsartan is effective in reducing high blood pressure, clinical data on the potential role of valsartan in PCC are currently limited. Therefore, the aim of this study was to investigate the effects of pretreatment with terazosin and valsartan on patients with PCC.MethodsIn this retrospective cohort study, 50 patients who underwent laparoscopic resection of PCC were enrolled. During preoperative preparation, the patients (n=25) in the control group were treated with terazosin, while those (n=25) in the combination treatment group were treated with terazosin and valsartan. The levels of catecholamine hormones before and after surgery were determined, and the intraoperative blood pressure and the incidence of complications were compared between the two groups.ResultsThe results showed no significant differences in baseline patient characteristics or surgical conditions between the two groups (p>0.05). However, on the third day after surgery, the levels of catecholamine hormones in the two groups were significantly lower than those before surgery (p<0.05), while the levels in the combination treatment group were notably lower than those in the control group (p<0.05). The patients in the combination treatment group showed lower intraoperative blood pressure fluctuations and incidence of perioperative complications compared with the control group (p<0.05).ConclusionsTerazosin combined with valsartan can effectively improve perioperative haemodynamic instability and reduce postoperative complications in the preoperative management of PCC.</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2020-002375</identifier><identifier>PMID: 32895230</identifier><language>eng</language><publisher>England: British Medical Journal Publishing Group</publisher><subject>Adrenal Gland Neoplasms - surgery ; Adrenergic receptors ; basic sciences ; Blood pressure ; Body mass index ; Catecholamines ; Catheters ; clinical pharmacy ; clinical trial medication ; Dopamine ; Drug dosages ; Heart rate ; Hemodynamics ; Hemodynamics - physiology ; Hormones ; Humans ; Hypertension ; Hypotension ; Laparoscopy ; Neuroendocrine tumors ; Original Research ; Patients ; pharmacy design ; Pheochromocytoma - surgery ; Prazosin - analogs & derivatives ; Retrospective Studies ; Surgery ; Surgical outcomes ; Urine ; Valsartan</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2022-07, Vol.29 (4), p.192-197</ispartof><rights>European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>European Association of Hospital Pharmacists 2020. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2022 European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ. 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b471t-660dba8922fdbb104fce5f812cf04116ab8be875f6df93fc926b74eb85150cf03</citedby><cites>FETCH-LOGICAL-b471t-660dba8922fdbb104fce5f812cf04116ab8be875f6df93fc926b74eb85150cf03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251171/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9251171/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32895230$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ji, Qingrong</creatorcontrib><creatorcontrib>Li, Feng</creatorcontrib><creatorcontrib>Zhang, Xianzhao</creatorcontrib><creatorcontrib>Wang, Yuqiang</creatorcontrib><creatorcontrib>Liu, Cunfei</creatorcontrib><creatorcontrib>Chang, Ying</creatorcontrib><title>Effects of pretreatment with terazosin and valsartan on intraoperative haemodynamics in patients with phaeochromocytoma</title><title>European journal of hospital pharmacy. Science and practice</title><addtitle>Eur J Hosp Pharm</addtitle><addtitle>Eur J Hosp Pharm</addtitle><description>ObjectiveSurgery is the primary strategy for treating phaeochromocytoma (PCC), but it can lead to severe hypertension and heart failure. Although valsartan is effective in reducing high blood pressure, clinical data on the potential role of valsartan in PCC are currently limited. Therefore, the aim of this study was to investigate the effects of pretreatment with terazosin and valsartan on patients with PCC.MethodsIn this retrospective cohort study, 50 patients who underwent laparoscopic resection of PCC were enrolled. During preoperative preparation, the patients (n=25) in the control group were treated with terazosin, while those (n=25) in the combination treatment group were treated with terazosin and valsartan. The levels of catecholamine hormones before and after surgery were determined, and the intraoperative blood pressure and the incidence of complications were compared between the two groups.ResultsThe results showed no significant differences in baseline patient characteristics or surgical conditions between the two groups (p>0.05). However, on the third day after surgery, the levels of catecholamine hormones in the two groups were significantly lower than those before surgery (p<0.05), while the levels in the combination treatment group were notably lower than those in the control group (p<0.05). The patients in the combination treatment group showed lower intraoperative blood pressure fluctuations and incidence of perioperative complications compared with the control group (p<0.05).ConclusionsTerazosin combined with valsartan can effectively improve perioperative haemodynamic instability and reduce postoperative complications in the preoperative management of PCC.</description><subject>Adrenal Gland Neoplasms - surgery</subject><subject>Adrenergic receptors</subject><subject>basic sciences</subject><subject>Blood pressure</subject><subject>Body mass index</subject><subject>Catecholamines</subject><subject>Catheters</subject><subject>clinical pharmacy</subject><subject>clinical trial medication</subject><subject>Dopamine</subject><subject>Drug dosages</subject><subject>Heart rate</subject><subject>Hemodynamics</subject><subject>Hemodynamics - physiology</subject><subject>Hormones</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Hypotension</subject><subject>Laparoscopy</subject><subject>Neuroendocrine tumors</subject><subject>Original Research</subject><subject>Patients</subject><subject>pharmacy design</subject><subject>Pheochromocytoma - surgery</subject><subject>Prazosin - analogs & derivatives</subject><subject>Retrospective Studies</subject><subject>Surgery</subject><subject>Surgical outcomes</subject><subject>Urine</subject><subject>Valsartan</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNkUuLFDEUhQtRnGGcfyAScOOmnLxTtRFkGB8w4EbXIUklVppOUibpHnp-vWlqpn0sxFUuud85nMvpupcIvkWI8Cu7mZdZ5dBjiGEPISaCPenOMaSiH0dOn55mxs-6y1K8hoyQYaRkfN6dETyMDBN43t3dOGdNLSA5sGRbs1U12FjBna8zqDar-1R8BCpOYK-2ReWqIkgR-FizSksDqt9bMCsb0nSIKnhT2hIs7b_5lNWohbXJzDmFZA41BfWie-aanb18eC-6bx9uvl5_6m-_fPx8_f6211Sg2nMOJ62GEWM3aY0gdcYyNyBsHKQIcaUHbQfBHJ_cSJwZMdeCWj0wxGBjyEX3bvVddjrYydhj7K1csg8qH2RSXv65iX6W39NejpghJFAzePNgkNOPnS1VBl-M3W5VtGlXJKYDIUwIKhr6-i90k3Y5tvMk5gPkXIyINIqulMmplGzdKQyC8liufCxXHsuVa7lN9ur3Q06ixyobcLUCOmz-1xL-Upyi_lPyE0MNxUQ</recordid><startdate>20220701</startdate><enddate>20220701</enddate><creator>Ji, Qingrong</creator><creator>Li, Feng</creator><creator>Zhang, Xianzhao</creator><creator>Wang, Yuqiang</creator><creator>Liu, Cunfei</creator><creator>Chang, Ying</creator><general>British Medical Journal Publishing Group</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20220701</creationdate><title>Effects of pretreatment with terazosin and valsartan on intraoperative haemodynamics in patients with phaeochromocytoma</title><author>Ji, Qingrong ; Li, Feng ; Zhang, Xianzhao ; Wang, Yuqiang ; Liu, Cunfei ; Chang, Ying</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b471t-660dba8922fdbb104fce5f812cf04116ab8be875f6df93fc926b74eb85150cf03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adrenal Gland Neoplasms - surgery</topic><topic>Adrenergic receptors</topic><topic>basic sciences</topic><topic>Blood pressure</topic><topic>Body mass index</topic><topic>Catecholamines</topic><topic>Catheters</topic><topic>clinical pharmacy</topic><topic>clinical trial medication</topic><topic>Dopamine</topic><topic>Drug dosages</topic><topic>Heart rate</topic><topic>Hemodynamics</topic><topic>Hemodynamics - physiology</topic><topic>Hormones</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Hypotension</topic><topic>Laparoscopy</topic><topic>Neuroendocrine tumors</topic><topic>Original Research</topic><topic>Patients</topic><topic>pharmacy design</topic><topic>Pheochromocytoma - surgery</topic><topic>Prazosin - analogs & derivatives</topic><topic>Retrospective Studies</topic><topic>Surgery</topic><topic>Surgical outcomes</topic><topic>Urine</topic><topic>Valsartan</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ji, Qingrong</creatorcontrib><creatorcontrib>Li, Feng</creatorcontrib><creatorcontrib>Zhang, Xianzhao</creatorcontrib><creatorcontrib>Wang, Yuqiang</creatorcontrib><creatorcontrib>Liu, Cunfei</creatorcontrib><creatorcontrib>Chang, Ying</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ji, Qingrong</au><au>Li, Feng</au><au>Zhang, Xianzhao</au><au>Wang, Yuqiang</au><au>Liu, Cunfei</au><au>Chang, Ying</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of pretreatment with terazosin and valsartan on intraoperative haemodynamics in patients with phaeochromocytoma</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><stitle>Eur J Hosp Pharm</stitle><addtitle>Eur J Hosp Pharm</addtitle><date>2022-07-01</date><risdate>2022</risdate><volume>29</volume><issue>4</issue><spage>192</spage><epage>197</epage><pages>192-197</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>ObjectiveSurgery is the primary strategy for treating phaeochromocytoma (PCC), but it can lead to severe hypertension and heart failure. Although valsartan is effective in reducing high blood pressure, clinical data on the potential role of valsartan in PCC are currently limited. Therefore, the aim of this study was to investigate the effects of pretreatment with terazosin and valsartan on patients with PCC.MethodsIn this retrospective cohort study, 50 patients who underwent laparoscopic resection of PCC were enrolled. During preoperative preparation, the patients (n=25) in the control group were treated with terazosin, while those (n=25) in the combination treatment group were treated with terazosin and valsartan. The levels of catecholamine hormones before and after surgery were determined, and the intraoperative blood pressure and the incidence of complications were compared between the two groups.ResultsThe results showed no significant differences in baseline patient characteristics or surgical conditions between the two groups (p>0.05). However, on the third day after surgery, the levels of catecholamine hormones in the two groups were significantly lower than those before surgery (p<0.05), while the levels in the combination treatment group were notably lower than those in the control group (p<0.05). The patients in the combination treatment group showed lower intraoperative blood pressure fluctuations and incidence of perioperative complications compared with the control group (p<0.05).ConclusionsTerazosin combined with valsartan can effectively improve perioperative haemodynamic instability and reduce postoperative complications in the preoperative management of PCC.</abstract><cop>England</cop><pub>British Medical Journal Publishing Group</pub><pmid>32895230</pmid><doi>10.1136/ejhpharm-2020-002375</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2047-9956 |
| ispartof | European journal of hospital pharmacy. Science and practice, 2022-07, Vol.29 (4), p.192-197 |
| issn | 2047-9956 2047-9964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9251171 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adrenal Gland Neoplasms - surgery Adrenergic receptors basic sciences Blood pressure Body mass index Catecholamines Catheters clinical pharmacy clinical trial medication Dopamine Drug dosages Heart rate Hemodynamics Hemodynamics - physiology Hormones Humans Hypertension Hypotension Laparoscopy Neuroendocrine tumors Original Research Patients pharmacy design Pheochromocytoma - surgery Prazosin - analogs & derivatives Retrospective Studies Surgery Surgical outcomes Urine Valsartan |
| title | Effects of pretreatment with terazosin and valsartan on intraoperative haemodynamics in patients with phaeochromocytoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T06%3A02%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20pretreatment%20with%20terazosin%20and%20valsartan%20on%20intraoperative%20haemodynamics%20in%20patients%20with%20phaeochromocytoma&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Ji,%20Qingrong&rft.date=2022-07-01&rft.volume=29&rft.issue=4&rft.spage=192&rft.epage=197&rft.pages=192-197&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2020-002375&rft_dat=%3Cproquest_pubme%3E2483357747%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2680667913&rft_id=info:pmid/32895230&rfr_iscdi=true |